CD274 and neoplasm: At a 1200 mg dose, which was recommended in phase 2, patients with PD-L1-positive (≥1% PD-L1+ tumour cells) and PD-L1-high (≥80% PD-L1+ tumour cells) cell counts had ORRs of 36.0% and 85.7%, respectively.